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Abstract: Sarcopenia refers to a decrease in skeletal muscle mass and function. Because sarcopenia
affects mortality, and causes significant disability, the clinical importance of sarcopenia is emerging.
At first, sarcopenia was recognized as an age-related disease but, recently, it has been reported
to be prevalent also in younger patients with autoimmune diseases. Specifically, the association
of sarcopenia and autoimmune diseases such as rheumatoid arthritis has been studied in detail.
Although the pathogenesis of sarcopenia in autoimmune diseases has not been elucidated, chronic
inflammation is believed to contribute to sarcopenia, and moreover the pathogenesis seems to be
different depending on the respective underlying disease. The definition of sarcopenia differs among
studies, which limits direct comparisons. Therefore, in this review, we cover various definitions of
sarcopenia used in previous studies and highlight the prevalence of sarcopenia in diverse autoimmune
diseases including rheumatoid arthritis, spondyloarthritis, systemic sclerosis, inflammatory bowel
disease, and autoimmune diabetes. In addition, we cover the pathogenesis and treatment of sarcopenia
in autoimmune and rheumatic diseases. This review provides a comprehensive understanding
of sarcopenia in various autoimmune diseases and highlights the need for a consistent definition
of sarcopenia.
Keywords: sarcopenia; rheumatic disease; autoimmune disease; rheumatoid arthritis; inflammatory
bowel disease; type 1 diabetes
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1. Introduction
The loss of muscle mass and function with aging is a natural phenomenon. In the seventh and
eighth decade of life, muscle strength decreases by 20–40% and the degree of reduction increases
gradually [1]. The decrease in skeletal muscle mass, strength, and function associated with aging is
termed sarcopenia [2–4]. Sarcopenia is associated with daily life disability, falls in older people, and a
high risk of all-cause mortality [5,6]. Furthermore, there is a financial burden associated with sarcopenia
because the hospitalization costs for patients with sarcopenia are significantly higher than those without
sarcopenia [7]. As the clinical importance of sarcopenia has become apparent, it is now considered to
be a disease entity in the International Classification of Diseases (ICD) [8]. Although sarcopenia is
usually considered to be an age-related disorder, younger people with various clinical conditions also
suffer from sarcopenia. Age-related sarcopenia with no other causes is called ”primary sarcopenia”,
whereas when one or more other causes such as malnutrition are evident, sarcopenia is classified
as ”secondary sarcopenia” [4]. In many cases, sarcopenia is age-related and is also a multifactorial
problem [9]. It is well known that endocrine diseases or malignancies promote sarcopenia [10].
Likewise, chronic inflammation is also a paramount risk factor for sarcopenia [10,11]. From this point of
view, autoimmune diseases with persistent chronic inflammation due to autoreactive immune response,
could be a risk factor for sarcopenia. Indeed, a recent study showed that having any autoimmune
disease was associated with sarcopenia with an odds ratio (OR) of 1.83 [12]. In addition, the association
between rheumatoid arthritis (RA) and sarcopenia is well established. Nevertheless, to date, there are no
comprehensive reviews regarding the relationship of sarcopenia and autoimmune diseases. This review
addresses this gap and covers the association between sarcopenia and autoimmune or rheumatic
diseases. This review mainly addresses RA rather than other diseases due to a difference in the
sufficiency of studies.
2. Definition and Diagnosis of Sarcopenia
In 1989, Irwin Rosenberg first coined the term “sarcopenia” (Greek “sarx” or flesh and “penia”
or loss) to define the decrease of skeletal muscle mass, however, until now there has been no unified
definition or diagnosis of sarcopenia [2,3]. Baumgartner et al. defined sarcopenia based on skeletal
muscle mass [13]. The skeletal muscle mass index (SMI) was defined as appendicular skeletal muscle
mass (ASM)/height2 (kg/m2), and sarcopenia was defined if the SMI was two standard deviations
below the mean of a gender-specific reference group [13]. After a few years, Janssen et al. proposed cut
points of height-adjusted skeletal muscle mass that were associated with a physical disability risk [14].
Later, several consensus groups proposed a definition using both muscle mass and function [4,15–18].
In 2010, the European Working Group on Sarcopenia in Older People (EWGSOP) defined sarcopenia as
“a syndrome characterized by progressive and generalized loss of skeletal muscle mass and strength
with a risk of adverse outcomes such as physical disability, poor quality of life and death”, a definition
that now represents the most widely used definition in the clinical realm [4]. According to the EWGSOP,
the definition of sarcopenia was (1) having low muscle mass and (2) having low muscle strength
or low physical performance [4]. The Foundation of the National Institute of Health (FNIH) [15],
the International Working Group on Sarcopenia (IWGS) [16], and the European Society on Clinician
Nutrition and Metabolism special interest groups (ESPEN SIG) [17] also proposed a definition for
sarcopenia that contained both muscle mass and function. The Asian Working Group for Sarcopenia
(AWGS) took a similar approach for sarcopenia but proposed a new and more appropriate cut-off value
for Asians, considering that already proposed cut-points had been calculated from Caucasian data [18].
Recently, the European Working Group on Sarcopenia in Older People 2 (EWGSOP2) revised the
definition of sarcopenia and characterized it by (1) low muscle strength and (2) low muscle quantity or
quality [19]. This change reflected the study results that muscle strength is a more important prognostic
factor than muscle mass [20–23].
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3. Epidemiology of Sarcopenia in Autoimmune and Rheumatic Disease Patients
Table 1 shows the prevalence of sarcopenia in autoimmune and rheumatic diseases. The prevalence
of sarcopenia varies based on the type of autoimmune disease, and also the different definitions used,
as well as the subject groups analyzed. Overall, the clinical definitions are heterogeneous. On the one
hand, many studies have defined sarcopenia using only one aspect, muscle mass or lean mass which are
calculated using the SMI or the free fat mass index (FFMI), respectively. On the other hand, other studies
have defined it using muscle mass plus muscle strength (e.g., handgrip strength) and performance
(e.g., TUG, timed up and go). Furthermore, the cut-off value for sarcopenia differs among studies.
The column ”definition of sarcopenia” highlights the respective criteria used to define sarcopenia.
Krajewska-Włodarczyk et al. demonstrated that the difference in definition affected study results [24].
In female patients with psoriatic arthritis (PsA), the prevalence of sarcopenia was 13.7, 49.0, and 43.1%,
respectively, when it was diagnosed using the following different definitions of SMI: (1) appendicular
muscle mass/height2 < 5.45 kg/m2 [13], (2) skeletal muscle mass/weight × 100 < 27.6% [25], (3) skeletal
muscle mass/weight × 100 < 27.6% with TUG > 14 s [25]. The heterogeneity of prevalence due to the
different definitions of sarcopenia makes the need for a unified definition and diagnostic criteria for
sarcopenia urgent.
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Table 1. Prevalence of Sarcopenia in Patients with Autoimmune and Rheumatic Diseases.
Author Prevalence (%) Patients (N) Group Feature p-Value Definition of Sarcopenia(Cut-off)
Rheumatoid Arthritis
Dao et al. [26] 1
Purely sarcopenic 18.1
105 Vietnamese, female
0.007
FFMI (Hull et al. [27])Sarcopenic obesity 2 12.4 0.002
Total 30.5 -
Santos et al. [28] 1
Purely sarcopenic 4.5
89 Caucasian, Portuguese, female
>0.05 3
FFMI z score ≤ −2
(Schutz et al. [29])Sarcopenic obesity
2 5.6 0.01
Total 10.1 -
Giles et al. [30]
Male 33.3 72
American
0.157 3
SMI (Janssen et al. [14])Female 21.4 117 0.004
Total 25.9 189 -
Dog˘an et al. [31] 43.3 30 Female,Age 35–50 0.004 SMI (Janssen et al. [14])
Tournadre et al. [32] 28.6 21 Active RA(DAS28 > 3.2) <0.05 SMI (Baumgartner et al. [13])
Lin et al. [33] 45.1 457 Chinese <0.05 4 SMI (AWGS [18])
Ngeuleu et al. [34] 39.8 123 Moroccan - SMI (Baumgartner et al. [13])
Tada et al. [35] 28.0 100 Japanese - AWGS [18]
Mochizuki et al. [36] 29.6 240 Japanese,age ≥ 65 - AWGS [18]
Torii et al. [37] 37.1 388 Japanese, female - EWGSOP [4], AWGS [18]
Vlietstra et al. [38] 17.1 82 New Zealander - SMI (FNIH [15])
Barone et al. [39] 21.0 76 Caucasian, Italian, age 40–75 - SMI (Janssen et al. [14]),HS (Lauretani et al. [40])
Spondyloarthritis
Ankylosing Spondylitis
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Table 1. Cont.
Author Prevalence (%) Patients (N) Group Feature p-Value Definition of Sarcopenia(Cut-off)
Barone et al. [39] 22.7 22 Caucasian, Italian, age 40–75 - SMI (Janssen et al. [14]),HS (Lauretani et al. [40])
El Maghraoui et al. [41] 34.3 67 Moroccan, male - EWGSOP [4]
Psoriatic Arthritis
Barone et al. [39] 20.0 70 Caucasian, Italian, age 40–75 - SMI (Janssen et al. [14]),HS (Lauretani et al. [40])
Krajewska-Włodarczyk et
al. [24]
13.7
51 Polish, age 50–75, female -
SMI (Baumgartner et al. [13])
49.0 SMI (Janssen et al. [25])
43.1 SMI(Janssen et al. [25]),TUG > 14s
Systemic Lupus Erythematosus
Santos et al. [28] 1
Purely sarcopenic 10.9
92 Caucasian, Portuguese, female
0.01
FFMI (Schutz et al. [29])Sarcopenic obesity 2 6.5 0.009
Total 17.4 -
Systemic Sclerosis
Caimmi et al. [42] 20.7 140 Italian - SMI (Baumgartner et al. [13])
Siegert et al. [43] 22.5 129 German, 91.5% female - EWGSOP [4]
Corallo et al. [44]
41.9
62 Caucasian, Italian -
SMI (Baumgartner et al. [13])
54.8 HS(Male < 30, Female < 20)
Inflammatory Bowel Disease
Ulcerative colitis
Zhang et al. [45] 27.3 99 Chinese. <0.05 SMI (Fearon et al. [46])
Cushing et al. [47] 69.5 82 Admitted for ASUC - SMI (Fearon et al. [46])
Mager et al. [48] 14.8 27 Age 5–18 - SMM z score < −2 [49]
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Table 1. Cont.
Author Prevalence (%) Patients (N) Group Feature p-Value Definition of Sarcopenia(Cut-off)
Bamba et al. [50] 48.3 29 Japanese - SMI (Nishikawa et al. [51])
Adams et al. [52] 50.0 14 American - SMI (Prado et al. [53])
Crohn’s Disease
Zhang et al. [45] 59.0 105 Chinese <0.05 SMI (Fearon et al. [46])
Mager et al. [48] 31.0 58 Age 5–18 - SMM z score < −2 [49]
Zhang et al. [54] 61.4 114 Chinese, required BR - SMI (Fearon et al. [46])
O’Brien et al. [55] 39.0 77 Retrospectively selected (BR) - SMI (Martin et al. [56])
Bamba et al. [50] 37.2 43 Japanese - SMI (Nishikawa et al. [51])
Thiberge et al. [57] 33.6 149 French - SMI (Mourtzakis et al. [58])
Adams et al. [52] 44.7 76 American - SMI (Prado et al. [53])
Lee et al. [59] 50.6 79 Korean - SMI (Kim et al. [60])
Cravo et al. [61] 31.0 71 Portuguese - SMI (Martin et al. [56])
Carvalho et al. [62] 41.4 58 Portuguese - SMI (Prado et al. [53])
Diabetes
Type 1 Diabetes Mellitus
Mori et al. [63] 16.6 36 Japanese - AWGS [18]
Latent Autoimmune Diabetes in Adults
Bouchi et al. [64] 35.0 20 Japanese 0.022 AWGS [18]
Autoimmune Liver Disease
(Autoimmune Hepatitis, Primary Biliary Cirrhosis, Primary Sclerosing Cholangitis)
Montano-Loza et al. [65] 41.8 55 Canadian, evaluated for LT - SMI (Martin et al. [56])
FFMI, free fat mass index; SMI, skeletal muscle mass index; RA, rheumatoid arthritis; DAS28, disease activity score in 28 joints; HS, handgrip strength; TUG, timed up and go; ASUC, acute
severe ulcerative colitis; SMM, skeletal muscle mass; BR, bowel resection; LT, liver transplantation. 1 Sarcopenia was divided into two groups, purely sarcopenic and sarcopenic obesity; 2
Sarcopenic obesity refers to a medical condition in which the loss of muscle is accompanied by increased fat mass; 3 Not statistically significant; 4 p-value was measured respectively
according to sex and age. Each p-value was <0.05.
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3.1. Rheumatoid Arthritis
Among the studies investigating the prevalence of sarcopenia in autoimmune diseases, most studies
have been performed in RA patients. Dao et al. [26], Santos et al. [28], Giles et al. [30], Dog˘an et al. [31],
Tournadre et al. [32], and Lin et al. [33] performed cross-sectional studies, and revealed that the overall
prevalence of sarcopenia was significantly higher in RA patients as compared with controls. In twelve
RA studies, as highlighted in Table 1, the prevalence of sarcopenia ranged from 10.1 to 45.1% and
the median value was 29.1% [26,28,30–39]. There are significant gaps among the figures. The gaps
seem to result from the diversity in the definition of sarcopenia and the different features of each
group such as drug use, disease activity, and ethnicity. In conclusion, RA patients are susceptible to
sarcopenia, but it is difficult to determine the exact prevalence of sarcopenia in RA from the studies
due to their heterogeneity.
3.2. Spondyloarthritis
We found three valid studies concerning the prevalence of sarcopenia in spondyloarthritis (SpA).
Barone et al. studied Caucasian SpA patients aged between 40 and 75 years, excluding those with
obesity; 22 patients with ankylosing spondylitis (AS) and 70 patients with PsA [39]. The prevalence of
sarcopenia diagnosed using the SMI and handgrip strength was 22.7% in AS, and 20.0% in PsA [39].
The difference in the prevalence of sarcopenia between RA, PsA, and AS was not significant, whereas
the prevalence of pre-sarcopenia (decreased muscle mass without reduced strength) was significantly
different (As > PsA > RA) in the study [39]. In male Moroccan AS patients, the prevalence of sarcopenia
was 34.3% according to the definition of the EWGSOP [41]. In another study of female patients with
PsA from Poland with an age range of 50 to 75 years, the prevalence of sarcopenia was 13.7, 49.0,
and 43.1%, each for different definitions [24].
3.3. Systemic Lupus Erythematosus
In the study by Santos et al., 16 out of 92 participants (17.4%) with a diagnosis of systemic lupus
erythematosus (SLE) were sarcopenic [28]. Among them, 10.9% of patients were sarcopenic but not
obese, and 6.5% patients were both sarcopenic and obese. Both numbers were significantly higher than
the controls (purely sarcopenic p = 0.01 and sarcopenic obesity p = 0.009).
3.4. Systemic Sclerosis
Three studies calculated the prevalence of sarcopenia in systemic sclerosis (SSc). The prevalence
was 20.7% when defining sarcopenia using the SMI [42] and 22.5% in a study from Germany,
which included 91.5% females and followed the definition of EWGSOP [4,43]. Another study
reported higher prevalence rates of 41.9 and 54.8% applying the SMI and handgrip strength criteria,
respectively [44].
3.5. Inflammatory Bowel Disease
To estimate the degree of sarcopenia in inflammatory bowel disease (IBD), a few studies used the
lumbar SMI assessed by computed tomography (CT) scan, dual-energy X-ray absorptiometry (DXA),
or bioelectrical impedance analysis (BIA). Zhang et al. observed that sarcopenia was more prevalent
in ulcerative colitis (UC) and Crohn’s disease (CD) as compared with controls (all p < 0.05) [45].
Among patients with IBD, the prevalence of sarcopenia was significantly higher in CD patients
(p < 0.05) [45]. The prevalence of sarcopenia in UC ranged from 14.8 to 69.5% [45,47,48,50,52].
The studies used the lumbar SMI to define sarcopenia with different cut-off points. The reason for this
large gap seems to result from the difference of respective inclusion criteria of the subjects. The highest
prevalence of 69.5% was measured in patients who were hospitalized due to acute severe UC [47],
and the lowest was in newly diagnosed patients with an age under 13 years [48]. In CD, the prevalence
of sarcopenia was higher than in other autoimmune diseases. It ranged between 31.0 and 61.4% and
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the median was 40.2% [45,48,50,52,54,55,57,59,61,62]. There are two reasons why the numbers could
have been overestimated. First, the subject groups were also skewed as described above for UC.
In fact, in general, the CT data, which was used to diagnose sarcopenia, was scarce in stable patients.
Therefore, subjects undergoing surgery after the CT scan were included to propose the frequency of
sarcopenia [54,55], or hospitalized due to disease exacerbation [50], or suspected complications of
CD [57]. Second, there could be an overlap between the two studies showing the highest prevalence
because the data were measured in an identical hospital in a similar time period [45,54].
3.6. Other Autoimmune Diseases
The prevalence of sarcopenia in type 1 diabetes mellitus (T1DM) and latent autoimmune diabetes
in adults (LADA) was 16.6 and 35.0%, respectively [63,64]. The subjects were Japanese, and sarcopenia
was diagnosed according to the AWGS. In LADA, the prevalence was significantly higher than in
controls [64]. Among Canadian autoimmune liver disease patients who were evaluated for liver
transplantation, 41.8% of the patients were sarcopenic as diagnosed using the SMI [65].
4. Rheumatoid Arthritis and Sarcopenia
RA is a chronic inflammatory autoimmune disease that affects multiple synovial joints. Sarcopenia
is a frequent comorbidity of RA that occurs in 10.1–45.1% of patients (Table 1). Occasionally, loss of
muscle is accompanied by increased fat mass which is called sarcopenic obesity. Rheumatoid cachexia
is a more serious condition and refers to the state of exhaustion and loss of overall body composition,
including muscle and fat [66]. It is also a common condition in RA with a prevalence of 15–32%
according to a meta-analysis [67]. Many studies have supported the idea that RA patients have lower
skeletal muscle mass resulting in a higher prevalence of sarcopenia as compared with those without
RA [26,31,68,69]. As shown in Table 2, sarcopenia in RA is clinically meaningful, since it is associated
with the incidence of low bone mineral density, falls, and fractures [36,37]. In addition, sarcopenic
RA patients have endothelial dysfunction and a higher cardiometabolic risk [34,70]. The Health
Assessment Questionnaire Disability Index (HAQ-DI) is a measure to assess the functional ability of
chronically ill patients, especially RA [71]. Several studies have reported that high HAQ-DI scores
are associated with sarcopenia in RA [30,33,72,73]. Study findings regarding sarcopenia and RA are
available in Table S1.
Table 2. Study Findings Related to Sarcopenia in Patients with Rheumatoid Arthritis.
Associated Factors
Age [36,37]
BMI [34–36]
Body fat mass [35,38]
Disease duration [37,74]
Bone erosion and mineral density [34,36]
Malnutrition and protein intake [37,72]
Joint damage [30,33,37]
Functional status (HAQ score) [26,30,33,72,73]
CRP level [30,36,68,72]
ESR [68,72]
RF [26,30]
MMP3 [35]
Use of GC [38,72,75,76]
Treatment
IL-6 inhibitor (TCZ) [32]
DMARDs [30,37]
β2-adrenoceptor agonist (formoterol) [77]
Antioxidant [78]
Neuromuscular electrical stimulation [79]
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Table 2. Cont.
Associated Factors
Risk
Falls [37]
Fractures [37]
Low bone mineral density [37]
Cardiometabolic risk [34]
Endothelial dysfunction [70]
Cytokines/Pathways
IL-1β [66,80]
IL-6 [81]
TNF- α [66,81]
NF-Kb [80]
p38 MAPK [80]
pSTAT3 [80]
Pax7 [80]
Myostatin [80]
MyoD [80,82]
Myogenin [80,82]
IGFBP-5 [82]
IGFBP-3 [82]
atrogin-1 [80,82]
MuRF-1 [80,82]
BMI, body mass index; HAQ, health assessment questionnaire; CRP, C-reactive protein; ESR, erythrocyte
sedimentation rate; RF, rheumatoid factor; MMP3, matrix metallopeptidase 3; GC, glucocorticoid; IL-6, interleukin-6;
TCZ, tocilizumab; DMARDs, disease-modifying antirheumatic drugs; IL-1β, interleukin-1β; TNF-α, tumor necrosis
factor-α; NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells; MAPK, mitogen-activated protein
kinase; pSTAT3, phospho-signal transducer and activator of transcription 3; Pax7, paired box 7; IGFBP, insulin-like
growth factor binding protein; MuRF-1, muscle RING-finger 1.
4.1. Associated Factors
The factors associated with sarcopenia in RA have been demonstrated in many studies (Table 2).
Old age [36,37], BMI [34–36], high body fat mass [35,38], longer disease duration [37,74], bone
erosion [34], low hip bone mineral density [36], malnutrition [37], low protein intake [72], and joint
damage [30,33,37] were all associated with sarcopenia. Acute phase reactants such as C-reactive
protein (CRP) and erythrocyte sedimentation rate (ESR) [30,36,68,72], rheumatoid factor (RF) [26,30],
and matrix metalloprotease 3 (MMP3) [35] were also associated. However, conflicting results have
been found for other factors. Disease activity, which was measured by the disease activity score in 28
joints (DAS28), was associated with abnormal body composition in one study [26], while others did
not find a significant association [30,34,35,38]. Tada et al. stated that no significant correlation between
sarcopenia and RA activity in their study could be due to the relatively mild disease activity of the
subjects [35].
4.2. Pathogenesis
Interleukin-1β (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α) are
proinflammatory cytokines which are thought to be pathogenic in RA. These cytokines are also
associated with sarcopenia and resting energy expenditure in RA patients, as shown in Figure 1 [66,80,81].
These relationships suggest that the inflammatory response of RA promotes sarcopenia. It has been
demonstrated from an animal study that muscle wasting in RA was due to the disease itself and
not associated with decreased mobility [83]. The exact mechanism of muscle wasting in RA has not
yet been elucidated in detail, but muscle wasting can be due to proteolysis by activated catabolic
responses and not due to decreased myogenic responses [82]. In adjuvant-induced arthritis (AIA)
rats, which is a model of arthritis-induced muscle wasting, increased gene expression of IL-1β
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accompanied with upregulation of E3 ubiquitin ligases (atrogin-1 and muscle RING-finger 1 (MuRF-1)),
phosphorylated p38 mitogen-activated protein kinase (MAPK)/p38 MAPK, and active nuclear factor
kappa-light-chain-enhancer of activated B cells (NF-κB) have been reported [80]. It is known that
NF-κB and p38 MAPK activate the ubiquitin proteasome system [84]. These signaling pathways are
related to muscle wasting in RA and they may be activated by IL-1β [80]. In contrast, myogenic
regulatory factors such as MyoD, paired box 7 (Pax7), and myogenin are also increased in animals
with muscle wasting [80]. These results suggest that muscle repair or anabolic compensation occur
simultaneously with muscle wasting.
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4.3. Treatments
Although available drugs for sarcopenia do not exist, it seems that treatment for RA is also
helpful for RA associated sarcopenia (Table 2). Although there have been conflicting results that have
indicated the use of disease-modifying antirheumatic drugs (DMARDs) was not related to changes in
body composition [30], a recent study has revealed that the use of biologic DMARD was negatively
associated with sarcopenia in RA [37]. A therapeutic possibility of a biologic DMARD, tocilizumab
(anti-IL6 receptor antibody), has also been proposed in other studies. From a prospective study in RA
patients, a year of treatment with tocilizumab increased lean mass and the SMI [32]. In addition, AIA rat
studies have suggested the possibility that β2-adrenoceptor agonist (formoterol) [77], antioxidants [78],
and neuromuscular electrical stimulation [79] could prevent skeletal muscle dysfunction or muscle
loss in RA. In contrast, treatment of RA using glucocorticoids (GCs) seemed to exacerbate sarcopenia.
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It has been reported that GCs use was positively associated with low lean mass or sarcopenia in RA
patients [38,72]. In a chronic polyarthritis mouse model, GCs treatment prevented inflammatory bone
loss but significantly increased muscle wasting [75]. A recent study by Yamada et al. revealed that after
administration of GCs for a year, 13.4% of the patients developed sarcopenia [76] and also, an average
GCs use of ≥3.25 mg/day over a year was significantly associated with sarcopenia with a OR of 8.81
(95% CI 1.146–7.9, p = 0.037) [76]. The results imply that GC treatment in RA patients should be used
cautiously and that reduction or stopping of GCs administration could alleviate treatment-related
sarcopenia. However, the duration of steroid use was not associated with sarcopenia [34].
5. Other Rheumatic Diseases and Sarcopenia
5.1. Spondyloarthritis
SpA is a group of rheumatic diseases characterized by inflammation in the axial skeleton and
peripheral joints, and by specific clinical symptoms such as uveitis and psoriasis [85]. SpA includes AS,
PsA, and other diseases, but previous studies only investigated sarcopenia in AS and PsA. As in other
rheumatic diseases, patients with SpA have been shown to be susceptible to sarcopenia [86], and it has
been associated with two major factors (Table 3, Table S2). First, sarcopenia was associated with disease
activity which was assessed using the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI).
Aguiar et al. highlighted that the SMI and the BASDAI have a significant negative correlation in male
AS and PsA patients [86]. In addition, the Bath Ankylosing Spondylitis Functional Index (BASFI) was
also correlated with sarcopenia in males [86]. Another study confirmed that in AS patients, sarcopenia
was associated with BASDAI [41]. Second, sarcopenia was associated with bone mineral abnormality.
Sarcopenic PsA patients had a significantly higher prevalence of osteoporosis than non-sarcopenic PsA
patients [24]. Another study showed that sarcopenia was associated with lower bone mineral density
in AS patients which supported this assumption [41]. However, other factors such as disease duration
were not associated with sarcopenia.
5.2. Systemic Sclerosis
SSc is an autoimmune rheumatic disease characterized by vasculopathy, tissue fibrosis, and internal
organ involvement [87]. SSc patients tend to have decreased muscle strength and endurance related to
physical functional disability [88] and 20.7–54.8% of patients exhibit sarcopenia [42–44]. Sarcopenia
in SSc has been associated with multiple organ involvements of the disease including lung, skin,
esophagus, microvasculature, and urinary tracts (Table 3, Table S2) [42,44,87]. Among the specific
characteristics of SSc, a longer duration of disease was also associated with sarcopenia [42,44,89].
In addition, low physical function [43], malnutrition [44], and high ESR [44] were also associated with
sarcopenia similar to the findings in RA (Table 3). In particular, elevated ESR in SSc reflected disease
severity well [90]. Considering all these results, sarcopenia seems to be related to the progression and
severity of SSc and muscle weakness and atrophy could result directly from muscle involvement of
SSc [91]. Thus, there could be a considerable overlap in domains of sarcopenia and muscle involvement
in SSc. Interestingly, sarcopenic patients receive more immunosuppressive drugs than non-sarcopenic
patients [43]. It is counterintuitive that alleviating disease activity with immunosuppressive drugs
is more related to sarcopenia. Siegert et al. interpreted that receiving more drugs indicated a more
severe state and a longer duration of disease [43]. Another study indicated that polypharmacy itself
could directly contribute to sarcopenia [92]. However, the association between the use of multiple
immunosuppressive drugs and sarcopenia needs further study. Interventional studies are still scarce
but there is a single study highlighting that medical nutrition therapy reversed sarcopenia in patients
with GI tract involvement of SSc [93].
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Table 3. Associated Factors Related to Sarcopenia in Patients with Rheumatic Diseases Other Than
Rheumatoid Arthritis.
Spondyloarthritis
BASDAI (in AS and male SpA) [41,86]
BASFI (in male SpA) [86]
Bone mineral density (in AS) [41]
Osteoporosis (in PsA) [24]
Systemic Sclerosis
Lung involvement (Medsger severity score) [42]
Skin involvement (mRSS, Medsger severity score) [42,44]
Microvascular involvement (capillaroscopy score) [44]
Esophageal involvement [44]
Overactive bladder [87]
Disease duration [42,44,89]
DLCO [42,44]
Malnutrition [44]
ESR [44]
BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Function
Index; mRSS, modified Rodnan skin score; DLCO, diffusing capacity for carbon monoxide; ESR, erythrocyte
sedimentation rate
6. Inflammatory Bowel Disease and Sarcopenia
IBD includes CD and UC which are characterized by chronic relapsing bowel inflammation.
The etiology of IBD remains unclear but environmental and genetic factors seem to be involved in
autoimmune pathogenicity [94,95]. In IBD patients, sarcopenia is frequent and the muscle mass reduces
over time accompanied by an increased BMI [96,97]. According to a follow-up study, the prevalence
of sarcopenia increased from 9.3 to 16.3% until a year after the diagnosis, although sarcopenia did
not increase after that time [97]. Sarcopenia in IBD has been studied for its prognostic implication
and associated factors (Table S3). It has been considered to be a predictive factor for medical rescue
therapy and bowel resection [47,50,52], and postoperative complications [54,62,98,99] in both CD and
UC. Additionally, in CD, sarcopenia is associated with primary non-response to anti-TNF treatment,
and therefore sarcopenic IBD patients need adjusted dosing [100]. The mechanism of sarcopenia in
IBD patients is believed to be associated with disease-related inflammation and nutritional problems.
Muscle radiation attenuation, which is an inverse parameter of muscle fat content [101], has been
associated with severe phenotypes of disease such as a history of a stricturing, penetrating complication,
or previous resection surgery for CD [61]. In addition, sarcopenia has been associated with high disease
activity assessed by the Mayo score in UC [45]. Inflammatory markers such as CRP and ESR, have been
associated with sarcopenia in IBD [59,99]. In addition, vitamin D in pediatric patients, as well as
hemoglobin and albumin in adult patients have been associated with sarcopenia [48,59]. Decreased
motility also seems to contribute to sarcopenia in pediatric patients [102]. Additionally, we suggest
a possibility that the gut microbiome could be related to sarcopenia in IBD. In IBD, the composition
and function of microbiome are altered. It has been reported that IBD patients have increased
proinflammatory bacterial species (Escherichia, Fusobacterium) and decreased anti-inflammatory
bacterial species (Faecalibacterium) with decreased amino acid biosynthesis of the microbiome [103].
In addition, it has been suggested that the gut microbiome could directly affect the muscle by
modulating amino acid bioavailability and the production of proinflammatory cytokines [104]. In an
acute leukemia mouse model, oral supplementation of lactobacillus species decreased atrogin-1,
MuRF1, and inflammatory cytokines [105]. A direct association of muscle and gut microbiome in
sarcopenic IBD should be investigated by animal and clinical studies. To alleviate sarcopenia in IBD,
treatment of the disease through reduction in inflammation would be effective. Infliximab, a TNF-α
antibody, increased both muscle volume and strength in CD patients [106], and moreover, colectomy
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increased SMI and serum albumin with a decrease in the prevalence of sarcopenia in UC patients [45].
Nutritional management could also be needed for better postoperative prognosis in sarcopenic IBD
patients, although it is not effective directly in the management of sarcopenia [54].
7. Autoimmune Diabetes and Sarcopenia
T1DM is a chronic autoimmune disease characterized by hyperglycemia due to pancreatic islet
β-cell destruction [107]. T1DM patients have a high prevalence of sarcopenia and hyperglycemia
is linked with low muscle function [63,108]. There are many factors that contribute to muscle
dysfunction in diabetes. Excessive intramyocellular lipid (IMCL) lowers muscle quality and could
impair muscle function [109]. Increased IMCL is frequently observed in T1DM patients [110].
Especially, increased IMCL is associated with poor glycemic control evaluated by hemoglobin A1c
(HbA1c) [111]. Accumulation of advanced glycation end-products, which are associated with persistent
hyperglycemia [112], is also thought to contribute to low muscle function in T1DM patients [63].
In addition, it has been reported that hyperglycemia is linked with muscle atrophy via a WW domain
containing E3 ubiquitin protein ligase 1 (WWP1)/Krüppel-like factor 15 (KLF15) pathway [113].
Hyperglycemia inhibits degradation of KLF15 via downregulation of WWP1 and increased KLF15
promotes proteolysis via upregulation of atrogin-1 and MuRF1 [113,114]. Moreover, hormones or
cytokines that are related to skeletal muscle are altered in T1DM. Diabetic patients appear to have higher
GC and IL-6 levels and both have catabolic effects [115–117]. Moreover, insulin-like growth factor-1
(IGF-1) which is well known for its contribution to skeletal muscle regeneration and development is
decreased with an alteration of the IGFBP [118–120]. Recently, mitochondrial dysfunction in T1DM
has been suggested as a primary contributor to muscle dysfunction. Mitochondrial changes in
T1DM-related sarcopenia are similar to that in age-related ones, and both include elevated oxidative
stress and mitochondrial-induced cell death [121]. LADA is a subtype of T1DM but has insulin
resistance similar to type 2 diabetes mellitus (T2DM) [122]. LADA had a higher risk of sarcopenia as
compared with controls and even T2DM groups in a cross-sectional study, but, so far, the association
between LADA and sarcopenia has not been elucidated in great detail [64].
8. Conclusions
In this in-depth review, we provide evidence that sarcopenia is common in different autoimmune
and rheumatic diseases. The exact prevalence differs among different studies, in part, due to the
different definitions of sarcopenia that are used. We propose that reporting sarcopenia in autoimmune
and rheumatic disorders is essential, since it contributes to morbidity and mortality among these
patients. Specific risk factors need to be confirmed in larger studies with a particular focus on treatment
strategies, i.e., cumulative dose of GC or other immunosuppressive measures. More detailed analyses
highlighting the role of chronic inflammation in the propagation of sarcopenia are needed.
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ICD International Classification of Diseases
OR Odds ratio
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RA Rheumatoid arthritis
SMI Skeletal muscle mass index
ASM Appendicular skeletal muscle mass
EWGSOP The European Working Group on Sarcopenia in Older People
FNIH The Foundation of the National Institute of Health
IWGS The International Working Group on Sarcopenia
ESPEN SIG The European Society on Clinician Nutrition and Metabolism special interest groups
AWGS The Asian Working Group for Sarcopenia
EWGSOP2 The European Working Group on Sarcopenia in Older People 2
FFMI Free fat mass index
PsA Psoriatic arthritis
TUG Timed up and go
SpA Spondyloarthritis
AS Ankylosing spondylitis
SLE Systemic lupus erythematosus
SSc Systemic sclerosis
IBD Inflammatory bowel disease
CT Computed tomography
UC Ulcerative colitis
CD Crohn’s disease
T1DM Type 1 diabetes mellitus
LADA Latent autoimmune diabetes in adults
HAQ-DI Health Assessment Questionnaire Disability Index
CRP C-reactive protein
ESR Erythrocyte sedimentation rate
IL-1β Interleukin-1β
IL-6 Interleukin-6
TNF-α Tumor necrosis factor-α
AIA Adjuvant-induced arthritis
MuRF-1 Muscle RING-finger 1
MAPK Mitogen-activated protein kinase
NF-κB Nuclear factor kappa-light-chain-enhancer of activated B cells
Pax-7 Paired box 7
DMARD Disease-modifying antirheumatic drug
GC Glucocorticoid
BASDAI Bath Ankylosing Spondylitis Disease Activity Index
BASFI Bath Ankylosing Spondylitis Functional Index
IMCL Intramyocellular lipid
WWP1 WW domain containing E3 ubiquitin protein ligase 1
KLF15 Krüppel-like factor 15
IGF-1 Insulin-like growth factor-1
IGFBP Insulin-like growth factor binding protein
T2DM Type 2 diabetes mellitus
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